Market News & Trends
Novozymes Biopharma's rAlbumin Approved in Japan
Novozymes Biopharma has recently announced that one of its leading customers has achieved approval of a medical device in Japan using Recombumin Alpha -…
West Announces Commercial Introduction of Novel Intradermal Adapter
West Pharmaceutical Services, Inc. recently announced the commercial introduction of its ID Adapter. West acquired a license to the technology in 2010 and has completed…
3/6/2013
Capsugel Announces Major Acquisition Capsugel recently announced it has acquired Encap Drug Delivery. Based in Scotland, Encap's focus on liquid and semi-solid encapsulation-based product development, and…
Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement
Althea Technologies, Inc. and Profectus BioSciences Inc. recently announced the signing of a manufacturing supply agreement for plasmid DNA production. Under the agreement, Althea…
2/27/2012
BASF & Bend Research Sign Bioavailability Agreement BASF SE and Bend Research Inc. have signed an agreement to jointly evaluate and develop novel excipients to…
BASF & Bend Research Sign Bioavailability Agreement
BASF SE and Bend Research Inc. have signed an agreement to jointly evaluate and develop novel excipients to enhance the solubility and bioavailability of…
BioCellChallenge Launches First Universal Delivery System for Transporting Antibodies Into Live Cells
BioCellChallenge SAS recently announced the launch of a new delivery system, ImmunoCellin, which is designed to transport antibodies into live cells even in the presence…
Capsugel Launches New Dosage Form Solutions Business Unit
Capsugel recently announced the launch of its Dosage Form Solutions (DFS) business unit to address growing customer demand for innovative product development and commercial…
Dow Chemical & Cambrex Collaborate to Manufacture Drug Solubility Solution
Cambrex and The Dow Chemical Company recently executed an agreement for Cambrex to contract manufacture Dow Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS) for Drug Solubility…
ProBioGen Signs Major Technology Deal for Therapeutic Antibody Platform
Another global pharma company has licensed ProBioGen's GlymaxX ADCC-enhancement technology. The license covers the modification of the pharma's antibody production platform for the generation…
Quinten Identifies Synergistic Markers; Predicts Favorable Response to TNBC Treatment
Quinten recently announced the identification of two discriminating biological marker candidates that are indicative of a favorable response to treatment in women suffering from triple-negative…
Nexavar Continues to Dominate Advanced Liver Cancer Therapy
Hepatocellular carcinoma (HCC), the most common form of liver cancer, carries a deadly reputation, and patients face shrinking hopes of new treatment options as…
Opioid Drug Abuse Will be Tackled Through New Delivery Methods
The opioid pain management market will continue to evolve throughout the coming years with new products and post-marketing studies that aim to reduce the…
Third Rock Ventures Launches Cancer Immunotherapeutics Company With $47 Million
Third Rock Ventures, LLC recently announced the formation of Jounce Therapeutics, Inc. with a $47 million Series A financing of the company. Jounce is…
2/20/2013
Argos Therapeutics Announces Updated Phase II Data Argos Therapeutics Inc. recently announced updated results from its Phase II study of AGS-003, its most advanced product…
93% Shares of OctoPlus Acquired
Dr Reddy's Laboratories (DRL), which is in the process of acquiring Netherlands-based speciality pharmaceutical company OctoPlus NV for about 27.4 million euro, has so…
Argos Therapeutics Announces Updated Phase II Data
Argos Therapeutics Inc. recently announced updated results from its Phase II study of AGS-003, its most advanced product candidate for the treatment of metastatic…
Biosimilars Market Expected to Soar
Top representatives from the healthcare industry were confirmed to attend the 2nd Biosimilars Congregation which took place in London on February 19 and 20.…
2/13/2013
Frost & Sullivan Sees Urgent Need for Cancer Diagnostics Tests; Finds Unmet Need for Key Disorders The range of potential therapeutic approaches available to treat…
Frost & Sullivan Sees Urgent Need for Cancer Diagnostics Tests; Finds Unmet Need for Key Disorders
The range of potential therapeutic approaches available to treat cancer is expected to expand rapidly during the next decade. Current diagnostic technologies focus on…
